Off-label Promotion: Allergan’s Pre-emptive Strike Against the FDA

In October 2009, Allergan, Inc. filed a complaint against the FDA seeking a ruling that would lift FDA restrictions against promoting drugs for "off-label" uses.  Allergan wants permission to share truthful information with the medical community so that physicians may properly evaluate the risks and benefits of Allergan's flagship product, Botox, for certain "off-label" treatments.  The resources on this page contain information about this important case and how it may impact the medical technology and life sciences industry.